Pancreatic Cancer Research

ResearcherScience for Life LaboratoryActive in the last 2 years

Gustav Jörgen Ullenhag

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4949-3267; OpenAlex author ID A5025004246. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 4

  1. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): resul… Co-author DOI 10.1016/s1470-2045(24)00079-2↗
  2. Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0169736↗
  3. Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. Last author DOI 10.1186/s12967-016-1037-z↗
  4. A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer. Co-author DOI 10.1371/journal.pone.0121197↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Angelica Loskog · 2 shared papers, 2016–2024 · strength 0.24
  2. Emma Eriksson · 2 shared papers, 2016–2024 · strength 0.24
  3. Maria Liljefors · 2 shared papers, 2015–2017 · strength 0.17
  4. Ann Marie Leen · 1 shared paper, 2024 · strength 0.16
  5. Eric Keith Rowinsky · 1 shared paper, 2024 · strength 0.16
  6. Linda C. Sandin · 1 shared paper, 2024 · strength 0.16
  7. Mohamed O. Othman · 1 shared paper, 2024 · strength 0.16
  8. Brandon George Smaglo · 1 shared paper, 2024 · strength 0.16
  9. Benjamin Musher · 1 shared paper, 2024 · strength 0.16
  10. Håkan Mellstedt · 1 shared paper, 2017 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.